Furthermore , this therapy could increase the dem and on radiation re sources .
There is no evidence on which to make a recommendation for patients with node-negative tumours that have not penetrated the muscularis propria .
For patients unable to undergo radiation , adjuvant chemotherapy alone may be of benefit , particularly for those with lymph-node metastases .
There is insufficient evidence from r and omized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
OBJECTIVE To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer ( T1 - 4 , N1 - 2 , M0 ) .
OPTIONS Neoadjuvant or adjuvant treatments compared with " curative " surgery alone .
OUTCOMES Overall survival , disease-free survival , and adverse effects .
The radiation fields used can possibly damage the left kidney , result ing in hypertension and other renal problems .
Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer.
A group of 243 patients with gastric cancer was subjected to a prospect i ve r and omized trial of adjuvant chemotherapy after curative gastrectomy . One of the three arms ( regimen A ) is induction therapy with a three-drug combination of mitomycin C ( MMC ) , 5-fluorouracil ( 5-FU ) , and cytosine arabinoside ( ara-C ) followed by intermittent oral administration of 5-FU for two years ( MFC + F ) . In regimen B , 5-FU in regimen A is replaced by ftorafur , administered on the same schedule as regimen A ( MF'C + F ' ) . Regimen C is the control , in which patients are treated by surgery alone . Regimen A was proven effective for the suppression of relapse in the limited groups of moderately locally advanced cancer ; five-year survival rates of the subset of stages I , II , and III were 72.1 % with regimen A and 53.1 % with regimen C ( P less than .05 ) . Regimen B yielded a better survival than the control , although the difference did not reach statistical significance . The results seem to favor 5-FU as adjuvant chemotherapy for gastric cancer
Furthermore , this therapy could increase the dem and on radiation re sources .
There is no evidence on which to make a recommendation for patients with node-negative tumours that have not penetrated the muscularis propria .
For patients unable to undergo radiation , adjuvant chemotherapy alone may be of benefit , particularly for those with lymph-node metastases .
There is insufficient evidence from r and omized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
OBJECTIVE To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer ( T1 - 4 , N1 - 2 , M0 ) .
OPTIONS Neoadjuvant or adjuvant treatments compared with " curative " surgery alone .
OUTCOMES Overall survival , disease-free survival , and adverse effects .
The radiation fields used can possibly damage the left kidney , result ing in hypertension and other renal problems .